Quantitative IgM and IgG Antibody Test Results Within 48 Hours
Phoenix, Ariz. (July 13, 2020) – Beacon Biomedical Inc, a Phoenix-based CLIA accredited high complexity laboratory commercializing blood-based tests for earlier cancer detection, has entered into an exclusive partnership with Inspire Diagnostics to provide quantitative COVID-19 IgM and IgG antibody testing in Arizona utilizing the AFIAS-6 platform for both fixed-based lab and mobile testing.
“The AFIAS-6 platform employs a patented fluorescence immunoassay technology that generates highly accurate quantitative COVID-19 IgM and IgG antibody test results in just 10-minutes.” says Donald F. Weber, CEO of Beacon. “These two antibodies are the first and second line of defense against the COVID-19 virus and work together to fight it as it progresses from its infectious to its non-infectious stage. By providing expedited baseline results and combining them with timed-interval successive test data for both IgM and IgG, we can now effectively track how our individual immune systems are responding to, and ultimately have dealt with, this virus including the possible immunity potential we may have built-up against it. We are thrilled to be able to support our Arizona community with this higher level of actionable COVID antibody testing.”
The average incubation period for the SARS-CoV-2 (COVID-19) virus is 5-6 days from the date of suspected exposure to infection, but it can range between 3-14 days depending on the individual. Once infected, you may experience symptoms (symptomatic) or not (asymptomatic). If asymptomatic, you simply will never know if you are infected and a carrier of the disease unless tested.
If symptoms develop, they will typically manifest within 3-5 day (av) post-infection. Some hallmark symptoms associated with COVID-19 infection include, but are not limited to, fever (88%), dry cough (68%), fatigue (38%) and coughing up of thick phlegm from the lungs (33%). You can be contagious for several weeks if you are symptomatic. However, if you are asymptomatic, the average shedding of the virus takes place in is 8-10 days. This is all determined by the body’s ability (or inability) to combat and manage the disease.
Quality test data can help manage back-to-work and quarantine strategies. However, its value is significantly diminished if it takes several days or weeks to get test results back from the lab. Beacon provides its quantitative COVID-19 IgM and IgG antibody test results within 48-hours of sample receipt. Individuals, practitioners and corporations interested in more detailed information can contact the company at 480.757.9037, email, firstname.lastname@example.org, or visit www.beaconbiomedical.com.
About Beacon Biomedical Inc.
Beacon Biomedical Inc. is a CLIA high complexity accredited proteomic diagnostics laboratory that develops and commercializing blood-based tests for earlier cancer detection. The company’s lead product, BeScreened™-CRC, is a blood-based test for the earlier detection of colorectal cancer. The company also provides quantitative SARS-CoV-2 (COVID-19) antibody testing. Beacon’s product development pipeline includes early detection assays for breast and lung cancers, and COVID-19 virus antigen testing. For more information visit, www.beaconbiomedical.com.
About Inspire Diagnostics
Inspire Diagnostics is a subsidiary of Inspire Health Alliance, a managed services provider and consultancy to the healthcare industry which works with healthcare providers to introduce innovative care models and state-of-the-art technologies into the market place that improve healthcare outcomes, lower costs and reduce risk. For more information visit, www.inspirediagnostics.com. ###